180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics

Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) has announced a new broadcast titled, “Controlling Inflammation to Stop Disease.” The company's research focuses on anti-TNF antibodies for autoimmune inflammatory diseases, suggesting significant market growth potential as new uses are identified. Ongoing clinical trials aim to address various disorders linked to inflammation. Collaborating with renowned institutions, 180 Life Sciences seeks to innovate treatments for unmet medical needs in inflammatory diseases. The company's lead program is currently in phase 2b/3 trials.

Positive

• Ongoing clinical trials for anti-TNF antibodies could lead to new treatment applications.
• Partnerships with prestigious universities may enhance research credibility and innovation.
• Lead program in phase 2b/3 trials indicates progress in drug development.

Negative

• None.

NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, “Controlling Inflammation to Stop Disease.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/VFpw9     

Ongoing research and clinical trials for anti-tumor necrosis factor (anti-TNF) antibodies in autoimmune inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn’s disease seem likely to only add to market growth and expansion as new anti-TNF uses are found. The wild card is that new findings implicate inflammation in a variety of other disorders with high unmet medical need. Research is ongoing and clinical trials are in progress with more planned for later this year. With any success, market forecasts many have to be adjusted substantially higher.

The founding team members at 180 Life Sciences Corp. (NASDAQ: ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics. 180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in both preclinical and clinical studies. By leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University, the company is leading new research into solving the complexities of inflammation to answer vast unmet medical needs.

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://nnw.fm/ATNF

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is the focus of 180 Life Sciences Corp. (NASDAQ: ATNF)?

180 Life Sciences focuses on developing novel drugs for inflammatory diseases, particularly using anti-TNF antibodies.

What recent announcement did 180 Life Sciences Corp. make?

180 Life Sciences announced a broadcast titled, “Controlling Inflammation to Stop Disease.”

What clinical trials is 180 Life Sciences Corp. currently conducting?

The company is conducting clinical trials for anti-TNF antibodies aimed at various autoimmune inflammatory diseases.

What stage is 180 Life Sciences' lead program currently in?

The lead program is currently in phase 2b/3 clinical trials.

How might new findings impact 180 Life Sciences Corp.'s market forecasts?

New findings could lead to adjustments in market forecasts, potentially increasing expectations for market growth.